{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:02:23Z","timestamp":1791133343308,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess the efficacy of oral NEPA (netupitant\u2010palonosetron 300\/0.50\u00a0mg) over multiple chemotherapy cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two randomized phase III studies evaluated a single dose of oral NEPA given on day 1 in chemotherapy\u2010naive patients receiving anthracycline\u2010cyclophosphamide (AC)\u2013based (Study 1) or highly (HEC)\/moderately (MEC) emetogenic chemotherapy (safety Study 2). Oral NEPA was compared with oral palonosetron 0.50\u00a0mg (Study 1) or oral aprepitant 125\u00a0mg\u00a0day 1, 80\u00a0mg\u00a0days 2\u20103\/palonosetron 0.50\u00a0mg (Study 2; no formal statistical comparisons). Oral dexamethasone was administered in all treatment groups. Complete response (CR; no emesis\/no rescue medication), no emesis, and no significant nausea (NSN) rates during acute (0\u201024\u00a0h) and delayed (&gt;24\u2010120\u00a0h) phases of chemotherapy cycles 1\u20104 in each study were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In Study 1, 1450 patients received 5969 chemotherapy cycles; in Study 2, 412 patients received 1961 chemotherapy cycles. In each study, \u226575% of patients completed 4 or more cycles. In Study 1, oral NEPA was superior to palonosetron in preventing chemotherapy\u2010induced nausea and vomiting (CINV) in the acute and delayed phases of cycle 1, with higher rates of CR (all <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), no emesis (all <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), and NSN (delayed phase <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05 cycles 1, 2, and 4) reported across 4 cycles. In Study 2, oral NEPA had numerically higher CR and NSN rates in the acute and delayed phases than aprepitant\u2010palonosetron in MEC\/HEC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Oral NEPA was highly effective in preventing both acute and delayed CINV over multiple chemotherapy cycles of HEC, AC, and MEC regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration numbers<\/jats:title><jats:p>Study 1, NCT01339260; Study 2, NCT01376297.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.2091","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T05:44:29Z","timestamp":1554875069000},"page":"2064-2073","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Fixed combination of oral NEPA (netupitant\u2010palonosetron) for the prevention of acute and delayed chemotherapy\u2010induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double\u2010blind phase III studies"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-3428","authenticated-orcid":false,"given":"Lee","family":"Schwartzberg","sequence":"first","affiliation":[{"name":"West Cancer Center Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Karthaus","sequence":"additional","affiliation":[{"name":"Staedt. Klinikum Neuperlach and Harlaching Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Rossi","sequence":"additional","affiliation":[{"name":"Helsinn Healthcare SA Lugano Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rizzi","sequence":"additional","affiliation":[{"name":"Helsinn Healthcare SA Lugano Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Borroni","sequence":"additional","affiliation":[{"name":"Helsinn Healthcare SA Lugano Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"University of California San Francisco Comprehensive Cancer Center San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology, Oncology and Rheumatology University of Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Hansen","sequence":"additional","affiliation":[{"name":"Northern Utah Associates Ogden Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0173-z"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706547"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0830"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156"},{"key":"e_1_2_7_6_1","article-title":"Oncologist perspectives on chemotherapy\u2010 induced nausea and vomiting (CINV) management and outcomes: A quantitative market research\u2010based survey","volume":"1","author":"Aapro M","year":"2018","journal-title":"Cancer Rep"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00674-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20230"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0018"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1042-3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-2-187"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx100"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2015.12.317"},{"issue":"5","key":"e_1_2_7_14_1","first-page":"273","article-title":"Resource utilization for chemotherapy\u2010induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens","volume":"8","author":"Schwartzberg L","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh110"},{"key":"e_1_2_7_16_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Antiemesis Version3.2018.http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed October 2018."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.08.049"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv138"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu110"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu101"},{"key":"e_1_2_7_23_1","unstructured":"2018 Helsinn Birex Pharmaceuticals Ltd. Dublin Ireland Akynzeo\u00ae (netupitant and palonosetron) [prescribing information]"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3502-x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu096"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq194"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000206"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11433"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.01.024"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4547"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv132"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00034-0"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00035-2"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2738-1"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.12.023"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.644"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.128"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.028"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21343"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0875-7"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.2091","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2091","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2091","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T13:15:09Z","timestamp":1731676509000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1002\/cam4.2091"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2091","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"2018-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}